Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256010 | 0.86 | MKNK1 (0.50) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL16256056 | 0.86 | SSTR4 (0.50) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL5264614 | 0.81 | MKNK1 (0.49) | SSTR4MKNK1DYRK1AKLK7HSD11B1 | |
| SCHEMBL2754298 | 0.79 | MET (0.48) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL16235511 | 0.78 | SSTR4 (0.42) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL84692 | 0.75 | MKNK1 (0.53) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL24654859 | 0.75 | SSTR4 (0.34) | SSTR4MKNK1DYRK1AKDM4EMEN1 | |
| SCHEMBL21016720 | 0.74 | MKNK1 (0.45) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL19295455 | 0.74 | MKNK1 (0.45) | SSTR4MKNK1DYRK1ADGAT1KLK7 | |
| SCHEMBL9924211 | 0.73 | DGAT1 (0.44) | SSTR4DYRK1ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8470851-B2 | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | SSTR4 3634/4885MKNK1 935/4885DYRK1A 4740/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SSTR4 2812/4885MKNK1 2777/4885DYRK1A 3616/4885 |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | SQSTM1, HSPA5, ATG7 | SSTR4 3942/4885MKNK1 524/4885DYRK1A 3287/4885 |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | SSTR4 3634/4885MKNK1 935/4885DYRK1A 4740/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SSTR4 4060/4885MKNK1 122/4885DYRK1A 1783/4885 |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | SSTR4 1933/4885MKNK1 4046/4885DYRK1A 4673/4885 |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | SSTR4 4788/4885MKNK1 133/4885DYRK1A 1525/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | SSTR4 1933/4885MKNK1 4046/4885DYRK1A 4673/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | SSTR4 1408/4885MKNK1 239/4885DYRK1A 2749/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | SSTR4 1933/4885MKNK1 4046/4885DYRK1A 4673/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | SSTR4 1933/4885MKNK1 4046/4885DYRK1A 4673/4885 |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SSTR4 4060/4885MKNK1 122/4885DYRK1A 1783/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SSTR4 2673/4885MKNK1 2911/4885DYRK1A 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.